Next, we validated the in vivo treatment effects on PI3K pathway member phospho-AKT (ser473) and proliferation marker PCNA, using immunohistochemistry on the ACC xenograft tissues. This evidence concerns the gene PIK3CG and adrenal cortex carcinoma.